Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Aileron Adds Scripps’s Click Chemistry

by Lisa M. Jarvis
December 6, 2010 | A version of this story appeared in Volume 88, Issue 49

Scripps Research Institute has licensed its click chemistry to Aileron Therapeutics. Aileron now has exclusive rights to use the Scripps technology in drug development and nonexclusive access in the development of diagnostics with its stabilized peptide and protein technologies. Cambridge, Mass.-based Aileron says access to the patent estate will accelerate the development of stapled peptides—peptides that are locked into their biologically active shape, thereby improving their druglike properties. Click chemistry uses small, reactive building blocks to quickly and reliably synthesize new compounds.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.